Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Researchers explored updated data from the AHA, noting that the number of CVD-related deaths increased from more than 874,000 in 2019 to more than 928,000 in 2020.
"The singular message to the public is that the optimal treatment for multivessel coronary artery disease—to improve not only long-term survival but also lower your risk of complications—is coronary artery bypass surgery," one specialist said in a statement.
A team of cardiologists and cardiac surgeons collaborated on the new analysis, reviewing data from more than 50,000 patients and developing a new risk model for clinicians.
Reducing total calorie intake and minimizing large meals, on the other hand, were both linked to improved weight loss. The study followed participants for an average of 6.3 years.
Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital and Harvard Medical School, explained some key takeaways from the PROMINENT trial.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
